Summary & Overview
HCPCS J8510: Busulfan, Oral 2 mg
HCPCS Level II code J8510 denotes Busulfan; oral, 2 mg, an oral chemotherapeutic agent commonly used in preparative regimens for hematopoietic stem cell transplantation and in select oncology treatments. Nationally, accurate coding of oral chemotherapy agents like J8510 is important for claims processing, drug utilization tracking, and payer coverage determinations because these drugs often involve specific authorization, benefit routing, and cost-sharing rules.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for J8510, typical sites of service where the drug is dispensed or administered, and the implications for billing lines that include an oral oncology agent. The publication summarizes common modifiers encountered on service lines, notes when data elements are not available in the input, and highlights where clinicians and billing staff should expect payer-specific policies to affect coverage and reimbursement workflows.
The article provides benchmarks and policy-oriented content relevant to national stakeholders: coding practice considerations for oral chemotherapy medications, payer coverage patterns, and operational impacts on service lines that process high-cost oral oncology agents. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J8510 represents Busulfan; oral, 2 mg. This code describes a specific oral chemotherapeutic drug formulation used in conditioning regimens for hematopoietic stem cell transplantation and certain oncology protocols.
-
Service type: Oral chemotherapy medication administration (prescription oral drug)
-
Typical site of service: Outpatient clinic, oncology infusion/chemotherapy clinic, hospital outpatient pharmacy, or patient's home when dispensed for oral administration
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult undergoing oral chemotherapy with J8510 (busulfan, oral, 2 mg) as part of a myeloablative conditioning regimen prior to hematopoietic stem cell transplantation or as disease-directed therapy for chronic myelogenous leukemia or other myeloproliferative disorders. The patient is managed in an oncology clinic or inpatient hematology/oncology unit. Clinical workflow includes baseline assessment (complete blood count, liver function tests, pulmonary function as indicated), informed consent, medication reconciliation, and scheduling of oral medication dispensing from the pharmacy. The pharmacy prepares unit-dosed oral tablets and documents lot numbers and expiration. Nursing provides education on dosing schedule, adverse effects (myelosuppression, hepatic toxicity, seizures), and infection precautions. During therapy, periodic laboratory monitoring for cytopenias and hepatic function occurs, with dose adjustments documented in the medical record. Medication administration is billed by the supplying facility or pharmacy using J8510 for each 2 mg unit dispensed, and appropriate service and place-of-service codes reflect outpatient infusion center, outpatient clinic, or inpatient hospital pharmacy dispensing as applicable.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Professional component |